Bliss raid! Vaccine giant official announcement: global offline! What's the secret| AstraZeng

　　 Trillion giant announced: global off the shelf!

　　 On May 8 local time, AstraZeneca, a British pharmaceutical company, announced that the company had begun to remove the new crown vaccine globally. The reasons given by the company are "commercial reasons" and vaccine surplus. The new vaccine, named Vaxzevria, is one of the main Covid-19 vaccines in the world. Since January 2021, more than 3 billion doses have been supplied, which once brought huge profits to AstraZeneca.

It is worth noting that on the eve of the announcement of the global withdrawal, AstraZeneca admitted that its new crown vaccine caused rare side effects and caused great panic. The company recently admitted in court documents that the new coronal vaccine Vaxzevria will lead to rare adverse coagulation and low platelet count and other side effects.

In the latest statement, AstraZeneca said that the decision to remove the vaccine had nothing to do with the court case or the company's recognition that the vaccine might cause side effects in some vaccinators.

Abruptly announced: global offline

On May 8 local time, AstraZeneca, a British pharmaceutical company, announced that since the COVID-19 pandemic, there has been a surplus of available vaccines, and the company has begun to remove COVID-19 vaccines globally.

　　 In the statement, the company said that this decision was due to commercial considerations. With the development of various vaccines to respond to the variant COVID-19, there has been an excess of available booster needles, which has led to a decline in the demand for the company's new COVID-19 vaccine. Therefore, AstraZeneca is withdrawing the vaccine globally and will also withdraw the marketing authorization of the vaccine in Europe.

The European Drug Administration also announced the withdrawal of the new crown vaccine on its official website, which means that AstraZeneca's new crown vaccine is no longer authorized to be marketed or sold in EU countries.

　　 The new vaccine, named Vaxzevria, is developed in cooperation with Oxford University and is one of the major Covid-19 vaccines in the world. Since the first vaccine was inoculated in Britain on January 4, 2021, more than 3 billion doses have been supplied and sold to more than 70 countries around the world.

It is reported that AstraZeneca's application to withdraw the Vaxzevria vaccine was submitted on March 5 this year and officially took effect on May 7, adding that the UK and other countries that have approved the vaccine will also submit similar applications.

AstraZeneca said that it would cooperate with regulators in other countries to "develop a clear way forward", including withdrawing the marketing authorization of the vaccine when no commercial demand is expected in the future.

AstraZeneca said: "We are extremely proud of the role Vaxzevria has played. Our efforts have been recognized by governments all over the world and are widely recognized as a key component of ending the global pandemic."

　　 AstraZeneca is a global innovative drug giant. Headquartered in London, UK, AstraZeneca has businesses in more than 100 countries around the world. Its broad product portfolio covers all kinds of prescription drugs, including the treatment of cardiovascular, respiratory, tumor, neurological and gastrointestinal diseases.

According to the 2023 financial report disclosed by the company, it achieved a revenue of 45.811 billion dollars in 2023, up 6% year on year; In the Chinese market, AstraZeneca's revenue reached US $5.876 billion, up 7% year on year.

Stimulated by the strong demand for the blockbuster anti-cancer drugs Imfinzi and Tagrisso and the newly launched Enhertu, AstraZeneca's total revenue in the first quarter of this year reached $12.7 billion, up 17% year on year, exceeding the market's expectation of $12 billion; Adjusted earnings per share excluding some items increased by 7% to $2.06, exceeding the market expectation of $1.89 per share.

　　 Affected by this, AstraZeneca's US share price continued to climb, rising to US $76.8 per share, a record high, with a total market value of more than US $235 billion (about 1700 billion yuan).

Major scandals

It is worth noting that on the eve of the announcement of the global withdrawal, AstraZeneca admitted that its new crown vaccine caused rare side effects and caused great panic.

　　 According to Reuters and the Daily Telegraph of Britain, AstraZeneca admitted in court documents that its new crown vaccine, Vaxzevria, can cause rare side effects such as poor blood coagulation and low platelet count. However, the company said that the decision to remove the vaccine had nothing to do with the court case or its acknowledgement that the vaccine might cause side effects for some vaccinators, saying the timing was purely coincidental.

This side effect has been identified as a condition called thrombosis with thrombocytopenia syndrome (TTS), which can lead to low levels of thrombus and platelets, which are blood cells that can prevent bleeding.

AstraZeneca is facing a class action lawsuit due to the related side effects of the vaccine. The company was accused of "the new crown vaccine developed jointly with Oxford University led to the death and serious injury of the vaccinators".

　　 TTS has caused at least 81 deaths and hundreds of serious injuries in the UK. According to the Daily Telegraph, the UK has received 51 cases so far. The victims and grieving relatives have sought compensation, which is estimated to be up to 100 million pounds.

Although AstraZeneca had previously raised objections to the above allegations, the company admitted in the legal document submitted in February this year that its new coronal vaccine "will lead to thrombosis and thrombocytopenia in very few cases, and its pathogenesis is still unclear".

In fact, the overseas market seems to have concluded the side effects of AstraZeneca's new coronal vaccine.

　　 As early as the beginning of 2021, due to the frequent occurrence of thrombosis symptoms and deaths, its new crown vaccine has been suspended or restricted in many European countries. Before that, in other countries and regions that have received the vaccine on a large scale, including Norway, Denmark and the United Kingdom, there have been many deaths and adverse reactions of vaccinators.

At that time, the European Drug Administration determined that AstraZeneca vaccine might cause abnormal thrombotic symptoms with thrombocytopenia. Later in 2021, the agency warned that capillary leakage syndrome was another side effect of AstraZeneca vaccine.

Despite the negative side, this new crown vaccine once brought huge profits to AstraZeneca. The Financial Times reported that in February 2022, AstraZeneca reported record breaking revenue, which was largely due to its COVID-19 vaccine and the sales brought by the acquisition of Alexion, a rare disease company worth 39 billion dollars. The report shows that AstraZeneca will achieve a total revenue of 37.417 billion US dollars (including COVID-19 vaccine) in 2021, a year-on-year increase of 41%, of which 4 billion US dollars will come from COVID-19 vaccine jointly developed by Oxford University.

When the stock market recovers, open an account first! Intelligent fixed investment, condition sheet, individual stock radar... for you>>